Latest News for Aozora Bank Stock (OTC:AOZOF)

Aozora Bank Ltd is a full-service commercial bank with operations primarily in Japan. The bank's activities are divided into six areas of focus, including retail banking, corporate finance, financial institutions, specialty finance, international, and financial markets. Most of its retail banking activities are focused on asset management consulting activities to drive sales of investment products, primarily in investment trusts and structured notes. Corporate finance is mostly focused on providing solutions to small and medium-sized enterprises. Its specialty finance business is mostly focused on real estate and business recovery. Aozora's financial markets business mostly engages in derivatives along with asset and liability management.

AOZORA BANK LTD ORD NEW by Aozora Bank Ltd.

Aozora Bank Ltd

Craig-Hallum analyst Matt Hewitt maintains Inotiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) with a Buy and lowers the price target from $25 to $10.

News

Price Target

Analyst Ratings

NOTV

Craig-Hallum Maintains Buy on Inotiv, Lowers Price Target to $10

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Checkpoint Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CKPT#NASDAQ">CKPT</a>) with a Buy and maintains $34 price target.

Reiteration

CKPT

HC Wainwright & Co. Reiterates Buy on Checkpoint Therapeutics, Maintains $34 Price Target

WIIM

MRVL

Marvell Technology shares are trading higher after Third Point disclosed a stake in the company in a 13F filing.

Eco Wave Power Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAVE#NASDAQ">WAVE</a>) reported quarterly losses of $(0.01) per share. This is unchanged from the same period last year.

Earnings

WAVE

Eco Wave Power Global Q1 EPS $(0.01), Same YoY

Wells Fargo analyst Andrew Nowinski maintains Dynatrace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) with a Overweight and lowers the price target from $75 to $60.

Wells Fargo Maintains Overweight on Dynatrace, Lowers Price Target to $60

Deep-pocketed investors have adopted a bullish approach towards Texas Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in TXN usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 13 extraordinary options activities for Texas Instruments. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 61% leaning bullish and 30% bearish. Among these notable options, 4 are puts, totaling $318,060, and 9 are calls, amounting to $422,588.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $190.0 and $220.0 for Texas Instruments, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Texas Instruments's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Texas Instruments's substantial trades, within a strike price spectrum from $190.0 to $220.0 over the preceding 30 days.
<h3>Texas Instruments 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715873801_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TXN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$1.83</td>
<td>$1.79</td>
<td>$1.83</td>
<td>$210.00</td>
<td>$138.4K</td>
<td>824</td>
<td style="text-align: right;">756</td>
</tr>
<tr>
<td>TXN</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$15.85</td>
<td>$15.55</td>
<td>$15.7</td>
<td>$200.00</td>
<td>$113.0K</td>
<td>43</td>
<td style="text-align: right;">115</td>
</tr>
<tr>
<td>TXN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$13.7</td>
<td>$13.5</td>
<td>$13.55</td>
<td>$195.00</td>
<td>$81.3K</td>
<td>98</td>
<td style="text-align: right;">60</td>
</tr>
<tr>
<td>TXN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$14.9</td>
<td>$14.75</td>
<td>$14.75</td>
<td>$200.00</td>
<td>$73.7K</td>
<td>2.1K</td>
<td style="text-align: right;">10</td>
</tr>
<tr>
<td>TXN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$16.0</td>
<td>$15.75</td>
<td>$15.9</td>
<td>$200.00</td>
<td>$68.3K</td>
<td>43</td>
<td style="text-align: right;">43</td>
</tr>
</tbody>
</table>

<h3>About Texas Instruments</h3>
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Following our analysis of the options activities associated with Texas Instruments, we pivot to a closer look at the company's own performance.
<h3>Where Is Texas Instruments Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 1,295,361, the TXN's price is down by -0.31%, now at $194.92. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 68 days.</li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Texas Instruments options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

Behind the Scenes of Texas Instruments's Latest Options Trends

Financial giants have made a conspicuous bearish move on Sunrun. Our analysis of options history for Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) revealed 9 unusual trades.
Delving into the details, we found 33% of traders were bullish, while 55% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $204,819, and 4 were calls, valued at $512,098.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $9.0 to $15.0 for Sunrun during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Sunrun's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Sunrun's substantial trades, within a strike price spectrum from $9.0 to $15.0 over the preceding 30 days.
<h3>Sunrun Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715873796_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RUN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/07/24</td>
<td>$0.74</td>
<td>$0.7</td>
<td>$0.74</td>
<td>$12.50</td>
<td>$333.0K</td>
<td>217</td>
<td>4.5K</td>
</tr>
<tr>
<td>RUN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$0.51</td>
<td>$0.5</td>
<td>$0.5</td>
<td>$11.50</td>
<td>$89.5K</td>
<td>758</td>
<td>1.8K</td>
</tr>
<tr>
<td>RUN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$4.5</td>
<td>$4.4</td>
<td>$4.5</td>
<td>$9.00</td>
<td>$62.9K</td>
<td>599</td>
<td>1</td>
</tr>
<tr>
<td>RUN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.1</td>
<td>$5.0</td>
<td>$5.1</td>
<td>$15.00</td>
<td>$50.4K</td>
<td>10.7K</td>
<td>100</td>
</tr>
<tr>
<td>RUN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.45</td>
<td>$4.3</td>
<td>$4.45</td>
<td>$14.00</td>
<td>$44.0K</td>
<td>5</td>
<td>100</td>
</tr>
</tbody>
</table>

<h3>About Sunrun</h3>
Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed either by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.
In light of the recent options history for Sunrun, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Sunrun</h3>
<ul>
<li>Trading volume stands at 2,858,462, with RUN's price down by -2.07%, positioned at $11.84.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 76 days.</li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Sunrun options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Market Whales and Their Recent Bets on RUN Options

Whales with a lot of money to spend have taken a noticeably bullish stance on Edwards Lifesciences.
Looking at options history for Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) we detected 12 trades.
If we consider the specifics of each trade, it is accurate to state that 58% of the investors opened trades with bullish expectations and 41% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $170,820 and 6, calls, for a total amount of $193,242.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $90.0 to $92.5 for Edwards Lifesciences over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Edwards Lifesciences's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Edwards Lifesciences's significant trades, within a strike price range of $90.0 to $92.5, over the past month.
<h3>Edwards Lifesciences 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715873791_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>EW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$5.9</td>
<td>$5.5</td>
<td>$5.8</td>
<td>$90.00</td>
<td>$37.7K</td>
<td>1.1K</td>
<td style="text-align: right;">129</td>
</tr>
<tr>
<td>EW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$5.8</td>
<td>$5.5</td>
<td>$5.8</td>
<td>$90.00</td>
<td>$37.1K</td>
<td>1.1K</td>
<td style="text-align: right;">64</td>
</tr>
<tr>
<td>EW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$6.0</td>
<td>$4.5</td>
<td>$6.0</td>
<td>$90.00</td>
<td>$34.8K</td>
<td>1.1K</td>
<td style="text-align: right;">349</td>
</tr>
<tr>
<td>EW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$4.5</td>
<td>$3.9</td>
<td>$3.9</td>
<td>$90.00</td>
<td>$32.7K</td>
<td>841</td>
<td style="text-align: right;">406</td>
</tr>
<tr>
<td>EW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$3.9</td>
<td>$3.8</td>
<td>$3.9</td>
<td>$90.00</td>
<td>$31.9K</td>
<td>841</td>
<td style="text-align: right;">82</td>
</tr>
</tbody>
</table>

<h3>About Edwards Lifesciences</h3>
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.
In light of the recent options history for Edwards Lifesciences, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Edwards Lifesciences</h3>
<ul>
<li>Trading volume stands at 599,038, with EW's price down by -0.01%, positioned at $90.15.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 69 days.</li>
</ul>
<h3>What The Experts Say On Edwards Lifesciences</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $93.2.
<ul>
<li>Maintaining their stance, an analyst from Evercore ISI Group continues to hold a In-Line rating for Edwards Lifesciences, targeting a price of $89. </li>
<li>An analyst from Deutsche Bank has elevated its stance to Buy, setting a new price target at $103. </li>
<li>Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Edwards Lifesciences, targeting a price of $101. </li>
<li>Maintaining their stance, an analyst from Piper Sandler continues to hold a Neutral rating for Edwards Lifesciences, targeting a price of $88. </li>
<li>Consistent in their evaluation, an analyst from Stifel keeps a Hold rating on Edwards Lifesciences with a target price of $85. </li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Edwards Lifesciences, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Edwards Lifesciences's Options: A Look at What the Big Money is Thinking

<a href="https://techcrunch.com/2024/05/16/ireland-privacy-watchdog-confirms-dell-data-breach-investigation/">https://techcrunch.com/2024/05/16/ireland-privacy-watchdog-confirms-dell-data-breach-investigation/</a>
&nbsp;
A top European privacy watchdog is investigating following the recent breaches of Dell customers' personal information, TechCrunch has learned.&nbsp;
Ireland's Data Protection Commission (DPC) deputy commissioner Graham Doyle confirmed to TechCrunch that the DPC has received "a breach notification on this matter" — referring to Dell — which is "currently under assessment." Asked to elaborate, Doyle declined to comment further.
An unnamed Dell spokesperson also confirmed that the technology giant "notified regulators and will continue to work with them as appropriate," when reached for comment by TechCrunch.
Last week, <a href="https://techcrunch.com/2024/05/09/dell-discloses-data-breach-of-customers-physical-addresses/">Dell alerted customers via email that it had experienced a data breach</a>. The theft, the company wrote, included customer names, physical addresses and Dell order information. Despite the theft of customers' physical addresses, Dell told customers that it believed "there is not a significant risk to our customers given the type of information involved."

DELL

'Ireland's Data Protection Commission Is Investigating Following The Recent Breaches Of Dell Customers' Personal Information' - TechCrunch

Craig-Hallum analyst Alexander Nowak assumes Celcuity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) with a Buy rating and raises Price Target to $27.

Initiation

CELC

Craig-Hallum Assumes Celcuity at Buy, Raises Price Target to $27

Vertical farming technology and infrastructure provider Nature&#8217;s Miracle Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMHI#NASDAQ">NMHI</a>) and Agrify Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGFY#NASDAQ">AGFY</a>) announced Thursday that both parties have signed a definitive agreement and merger plan.
Under the deal, a new wholly-owned subsidiary of Nature&#8217;s Miracle will merge with and into Agrify, which will survive as a wholly-owned subsidiary of Nature&#8217;s Miracle.
The signing of the agreement directly follows the previously announced term sheet for the merger, according to a press release.
<h3 class="wp-block-heading">Deal Details</h3>
Pursuant to the agreement, shareholders of Agrify will be issued 0.45 of a share of Nature&#8217;s Miracle common stock for each share of Agrify common stock they hold. Agrify shareholders are anticipated to collectively own roughly 30% of the post-merger common stock of the combined companies.
Additionally, Nature&#8217;s Miracle agreed to purchase and guarantee certain senior and junior notes issued by Agrify with a combination of cash and Nature&#8217;s Miracle stock.
<h3 class="wp-block-heading">Why It Matters</h3>
The deal is expected to bring a meaningful revenue stream for Nature's Miracle through Agrify's powerful SaaS and AI technology, which can be applied to the former's vertical farming business, the company said. Agrify also has a significant market share in cannabis extraction as it continues to drive revenue growth.
The merger would also result in a combination of management teams of both Miracle and Agrify.
See also: <a href="https://www.benzinga.com/markets/cannabis/24/04/38293686/ancillary-cannabis-co-s-stock-surges-on-news-of-merger-with-california-provider-of-cea-products-">Ancillary Cannabis Co.&#8217;s Stock Surges On News Of Merger With California Provider Of CEA Products And Solution</a>
<h3 class="wp-block-heading">What's Next</h3>
The transaction is expected to close in the second half of 2024, subject to shareholder approval and other customary closing conditions.
Once the merger is completed, the management will focus on increasing Nature&#8217;s Miracle&#8217;s market share supported by the alliance of the core business segments of each company including LED lighting, grow feed, indoor farming control systems, AI-enabled technology and software, and operations to source product in Asia and expand manufacturing in the U.S.
&#8220;As we work towards merger completion, we are confident that the &#8220;one&#8221; Nature&#8217;s Miracle and Agrify business will result in significant market share growth as consumer adoption increases across the vertical farming agriculture industry," James Li, Nature&#8217;s Miracle CEO said.
Raymond Chang, CEO and chairman of the board of Agrify, praised the new collaboration.
"The combined forces of Agrify and Nature&#8217;s Miracle will elevate our innovative, disruptive, and high-quality technology and service offerings for both the cannabis and agriculture industries," he said. &#8220;We believe the cannabis industry needs consolidation."
Some industry experts anticipated the consolidation trend to grow in the space. Ultimately, the industry will consolidate down to "five or six players," said MariMed CEO Jon Levine at one of previous Benzinga events. And, based on current trends, that's where the industry is heading "in the foreseeable future," according to Miles.
The 19th Benzinga Cannabis Capital Conference is returning to Chicago this Oct. 8-9. <a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">Get your tickets now</a> before prices surge by following <a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">this link</a>.
<h3 class="wp-block-heading">NMHI Price Action</h3>
Nature&#8217;s Miracle's shares traded 4.42% higher at $0.8677 per share during the pre-market session on Thursday morning.
<h3 class="wp-block-heading">AGFY Price Action</h3>
Agrify's shares traded 2.04% higher at $0.3 per share during the pre-market session on Thursday morning.

Cannabis

AGFY

NMHI

Cannabis Cultivation Solutions Provider Agrify And California's Nature's Miracle Sign Definitive Merger Deal

Thursday,&nbsp;AstraZeneca Plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>)&nbsp;<a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2024/supernova-trial-met-covid-19-prevention-endpoint.html" rel="noreferrer noopener">released</a>&nbsp;high-level results from the SUPERNOVA Phase 3 COVID-19 pre-exposure prophylaxis (prevention) trial.
The study showed AstraZeneca's&nbsp;sipavibart&nbsp;(formerly AZD3152), an investigational long-acting antibody (LAAB), demonstrated a statistically significant reduction in the incidence of symptomatic&nbsp;COVID‑19 compared to control (tixagevimab/cilgavimab&nbsp;or placebo) in immunocompromised patients.
The trial met both dual primary endpoints: Relative risk reduction of symptomatic COVID-19 caused by any SARS-CoV-2 variant and the relative risk reduction of infections caused by SARS-CoV-2 variants not containing the F456L mutation.&nbsp;
SUPERNOVA demonstrated the potential benefit of&nbsp;sipavibart&nbsp;in an evolving variant landscape.
Immunocompromised people include those with blood cancer, organ transplant recipients, patients with end-stage renal disease requiring dialysis, patients receiving B-cell depleting therapy within the past year, and those taking immunosuppressive medications, AstraZeneca said.
Despite accounting for approximately 4% of the population, immunocompromised patients make up about 25% of COVID-19 hospitalizations, ICU admissions, and deaths, even after multiple doses of COVID-19 vaccines.
Sipavibart&nbsp;was well tolerated&nbsp;in the trial and preliminary analyses&nbsp;show&nbsp;adverse events were balanced&nbsp;between the control and&nbsp;sipavibart&nbsp;arms.
The data will&nbsp;be presented&nbsp;at a forthcoming medical meeting. AstraZeneca is in dialogue with regulatory authorities on potential authorization or approval pathways.
AstraZeneca licensed Sipavibart in&nbsp;May 2022 from RQ Biotechnology.
Recently, AstraZeneca&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38694517/astrazeneca-pulls-plug-on-vaxzevria-covid-19-vaccine-amid-surplus-of-updated-vaccines" rel="noreferrer noopener">declared a worldwide cessation</a>&nbsp;of its COVID-19 vaccine, Vaxzevria, due to an "excess of updated vaccines."
Last month, AstraZeneca, while&nbsp;contesting the claims alleging its vaccine caused death and&nbsp;serious&nbsp;injury, has acknowledged in court documents that its vaccine can, in rare instances, cause thrombosis with Thrombocytopenia Syndrome (TTS), a condition characterized by blood clots and&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38500072/astrazeneca-admits-its-covid-19-vaccine-may-cause-blood-clotting-side-effect-in-very-rare-case-bu" rel="noreferrer noopener">low&nbsp;blood&nbsp;platelet counts</a>.
Price Action: AZN shares are down 0.04% at $76.94 at the last check on Thursday.
Image by Lydia Ilyakhina via Shutterstock

Biotech

Large Cap

Health Care

General

AstraZeneca's COVID-19 Prevention Therapy Cuts Risk Of Infection In Patients With Weaker Immunity, Data Shows

To gain an edge, this is what you need to know today.
<img alt="" src="https://thearorareport.com/wp-content/uploads/2024/05/2024-05-16_08h18_52.png" style="height:384px; width:624px" />
<h3>A Tell Ahead</h3>
Please <a href="https://thearorareport.com/chart-analysis-stock-market-wealthier-consumer-walmart-earnings-wmt-mc-05162024">click here</a> for an enlarged chart of Walmart Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wmt#NYSE">WMT</a>)
Note the following:
<ul>
<li>This article is about the big picture, not an individual stock.&nbsp;The chart of WMT stock is being used to illustrate the point.</li>
<li>Walmart is the largest retailer in the U.S., for this reason Walmart&nbsp;earnings are very important to the stock market.</li>
<li>The chart shows that WMT stock has broken out of the resistance zone on earnings.</li>
<li>RSI on the chart shows that WMT stock is now over bought.</li>
<li>In The Arora Report analysis, the follow up to the initial WMT breakout will be a tell for the entire stock market with the exception of tech stocks.&nbsp;If the breakout leads to a further rally, it will be a positive.&nbsp;If the breakout fails, it will be a negative.&nbsp;&nbsp;</li>
<li>WMT earnings are above the consensus and whisper numbers. Here are the details:
<ul>
<li>Q1 earnings came at $0.60 vs. $0.52 consensus.</li>
<li>Q1 revenues came at $161.51B vs. $159.5B consensus.</li>
<li>U.S. comp sales rose 3.8%.</li>
<li>WMT projects Q2 EPS of $0.62 - $0.65 vs. $0.64 consensus.</li>
<li>WMT projects FY25 EPS at the high or slightly above&nbsp; $2.23 - $2.37 vs. $2.36 consensus.</li>
</ul>
</li>
<li>In The Arora Report analysis, Walmart is beating estimates because it is attracting wealthier consumers who previously did not shop at Walmart.&nbsp;This is the result of consumers seeking value as a result of high inflation.&nbsp;Walmart is benefiting from inflation.</li>
<li>As full disclosure, WMT is in The Arora Report&#39;s&nbsp;ZYX Buy Model Portfolio.&nbsp;It is long from $19.25.&nbsp;&nbsp;</li>
<li>Initial jobless claims came at 222K vs. 218K consensus, but whisper numbers were running around 240K.&nbsp;In the early trade, stock market bulls are not liking this number.&nbsp;Upon release of this data, some selling came into the stock market. Stock market bulls&rsquo; reason that the Fed is more likely to cut rates earlier if jobless claims rise.&nbsp;As we have written before, this data is volatile.&nbsp;Investors should look at a four week moving average and not get carried away based on week to week fluctuations.&nbsp;Initial jobless claims is a leading indicator and carries heavy weight in our adaptive&nbsp;<a href="https://thearorareport.com/ALLOCATION%2BMODELS.htm" rel="nofollow" target="_blank">ZYX Asset Allocation Model</a>&nbsp;with inputs in&nbsp;<a href="https://thearorareport.com/unique-zyx-asset-allocation-4/" rel="nofollow" target="_blank">ten categories</a>.&nbsp;In plain English, adaptiveness means that the model changes itself with market conditions.&nbsp;Please&nbsp;<a href="https://thearorareport.com/unique-zyx-asset-allocation-3/" rel="nofollow" target="_blank">click here</a>&nbsp;to see how this is achieved.&nbsp; Most models on Wall Street are static.&nbsp;They work for a while and then stop working when market conditions change.</li>
<li>The Fed&rsquo;s Neel Kashkari said the Fed is likely to keep interest rates unchanged a bit longer. </li>
<li>More Fed speak is ahead from the Fed&rsquo;s Barkin, Harker, Mester and Bostic.</li>
</ul>
<h3>Housing</h3>
Housing starts came at 1.36M vs. 1.44M consensus.&nbsp;Building permits came at 1.44M vs. 1.48M consensus.
In The Arora Report analysis, the data indicates that the red hot market for new houses is beginning to cool.&nbsp;&nbsp;
<h4>Magnificent Seven Money Flows</h4>
In the early trade, money flows are positive in NVIDIA Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvda#NASDAQ">NVDA</a>).
In the early trade, money flows are neutral in Apple Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aapl#NASDAQ">AAPL</a>), Amazon.com, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amzn#NASDAQ">AMZN</a>), Alphabet Inc Class C (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/goog#NASDAQ">GOOG</a>), Microsoft Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/msft#NASDAQ">MSFT</a>),&nbsp;and Tesla Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>).
In the early trade, money flows are negative in Meta Platforms Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meta#NASDAQ">META</a>).
In the early trade, money flows are neutral in SPDR S&amp;P 500 ETF Trust (ARCA:SPY) and Invesco QQQ Trust Series 1 (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qqq#NASDAQ">QQQ</a>).
<h3>Momo Crowd And Smart Money In Stocks</h3>
The momo crowd is buying stocks in the early trade.&nbsp;Smart money is inactive in the early trade.
Note for new investors: Smart money often sells into the strength generated by momo crowd buying and buys into the weakness generated by momo crowd selling.&nbsp;Over a long period of time, investors come out ahead by adopting smart money&rsquo;s ways.&nbsp;The exception is in a raging bull market &ndash; for very, very short term trades, consider following the momo crowd and not smart money.
<h3>Gold</h3>
The momo crowd is buying gold in the early trade.&nbsp;Smart money is inactive in the early trade.
For longer-term, please see gold and silver ratings.
The most popular ETF for gold is SPDR Gold Trust (ARCA:GLD). The most popular ETF for silver is iShares Silver Trust (ARCA:SLV).&nbsp;
<h3>Oil</h3>
The momo crowd is buying oil in the early trade.&nbsp; Smart money is inactive in the early trade.
For longer-term, please see oil ratings.
The most popular ETF for oil is United States Oil ETF (ARCA:USO).
<h3>Bitcoin</h3>
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is continuing its run along with speculative stocks after CPI data yesterday and is now trading above $66,000.
<h3>Protection Band And What To Do Now</h3>
It is important for investors to look ahead and not in the rearview mirror.
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.&nbsp;The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp;If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp;A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp;When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.
<h3>Traditional 60/40 Portfolio</h3>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of seven year duration or less.&nbsp;Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

$BTC

AAPL

AMZN

GOOG

MSFT

NVDA

TSLA

Walmart Attracts Wealthier Consumers – Stock Market Tell, Red Hot New Housing Slows

Craig-Hallum analyst Jason Kreyer maintains Magnite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNI#NASDAQ">MGNI</a>) with a Buy and raises the price target from $18 to $20.

MGNI

Craig-Hallum Maintains Buy on Magnite, Raises Price Target to $20

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) with a Buy and maintains $2 price target.

MBIO

HC Wainwright & Co. Reiterates Buy on Mustang Bio, Maintains $2 Price Target

<ul>
<li>Cummins is raising its long-term financial targets as a result of its strengthening portfolio and continued execution on both its strategy and commitments.</li>
<li>Cummins is well-positioned to meet customer needs, drive real-world greenhouse gas reductions and generate growth regardless of the pace of the transition to zero emissions.</li>
<li>Cummins will continue to drive further improvement in its base business while successfully scaling AcceleraTM by Cummins, delivering profitable growth and higher operating cash flow.</li>
</ul>

Cummins Raises Long-Term Financial Targets As The Co Strengthens Its Portfolio; Terms Not Disclosed

William Blair analyst Sharon Zackfia downgrades Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) from Outperform to Market Perform.

Downgrades

William Blair Downgrades Under Armour to Market Perform

Graphic Packaging Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPK#NYSE">GPK</a>) has outperformed the market over the past 15 years by 7.52% on an annualized basis producing an average annual return of 20.15%. Currently, Graphic Packaging Holding has a market capitalization of $8.59 billion. 
Buying $1000 In GPK: If an investor had bought $1000 of GPK stock 15 years ago, it would be worth $15,444.44 today based on a price of $27.94 for GPK at the time of writing.
<h3>Graphic Packaging Holding's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715873420_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

If You Invested $1000 In This Stock 15 Years Ago, You Would Have $15,000 Today

ATI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATI#NYSE">ATI</a>) has outperformed the market over the past 5 years by 8.69% on an annualized basis producing an average annual return of 21.8%. Currently, ATI has a market capitalization of $7.75 billion. 
Buying $100 In ATI: If an investor had bought $100 of ATI stock 5 years ago, it would be worth $273.56 today based on a price of $62.30 for ATI at the time of writing.
<h3>ATI's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715873415_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 5 Years Ago, You Would Have $300 Today

California homeowners who were looking for relief from high insurance premiums may want to brace themselves for a nasty surprise if they carry Travelers Insurance. The national insurance giant recently announced they would be hiking homeowners' premiums in the Golden State by an average of 15.3%. The move will affect an estimated 320,000 policyholders and goes into effect in June of this year.
Although the average premium increase is 15%, some homeowners will see their rates increase by as much as 25%, which will only place further strain on the budgets of California homeowners. As hard as it may be to believe, the homeowners receiving the premium increases may be the lucky ones in this equation. Travelers also announced plans to cancel 6,600 policies for California homeowners.
The New York-based insurer is citing the increased risk and costs associated with wildfires and other natural disasters like mudslides or floods as the motivation behind both the premium increases and the cancellations. Regardless of whether they received a policy increase or a cancellation, the homeowners affected by this move will find a very difficult market waiting for them if they try to shop for new rates or a replacement policy.
Don't Miss:
<ul>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">Here's how you can collect passive rental income without being a landlord</a>.</li>
<li>Elon Musk and Jeff Bezos are bullish on one city that could dethrone New York and become the new financial capital of the US. <a href="https://www.benzinga.com/money/miami-take-new-yorks-place-financial-capital">Investing in its booming real estate market has never been more accessible</a>. </li>
</ul>
In recent years, California's<a href="https://www.benzinga.com/news/24/05/38859697/chubb-stock-climbs-after-berkshire-hathaway-purchases-shares"> insurance market </a>has been getting increasingly difficult for consumers as more and more insurers opt to quit the market entirely rather than deal with the risk of writing policies. In addition to Travelers, major insurance carriers with national recognition like State Farm, Allstate, and Farmers have recently reduced policies and dramatically raised premiums for the policies they renewed.
As recently as March, State Farm announced it would drop 72,000 California homeowners' policies. Like Travelers, all the insurers backing out of California are making these moves based on their fears over covering natural disasters, which are striking the state with more frequency and potency every year. In what can only be taken as an acknowledgment of the deep challenges facing the industry, California's Insurance Commission approved Travelers' rate increases.&nbsp;
Travelers released a statement to Los Angeles-based KTLA News about the increases, which said in part "The approved adjustments to our California homeowner's insurance rates are a necessary step toward aligning pricing to the risks that our customers are facing." The increases, from Travelers, also come on the heels of a recent proposal by California's Insurance Commissioner to let insurers use predictive modeling to calculate rate increases.
Trending:
<ul>
<li>Want to Create a Passive Income Stream? <a href="https://www.benzinga.com/real-estate/23/05/32554601/want-to-grow-your-wealth-passively-these-high-yield-real-estate-notes-might-be-your-holy-grail">These High-Yield Real Estate Notes Might Be Your Holy Grail</a></li>
</ul>
The Commissioner is also proposing to streamline and expedite the process of approving rate increases. Both moves could pave the way for even higher insurance premiums because currently, insurers are limited to using actual losses from past claims as the basis for rate increases. That specific limitation was introduced in 1988 under a measure known as Proposition 103 which also required insurers to get California Insurance Commission approval before increasing rates.
Since then, property values in California have skyrocketed and insurers say the current model for calculating rates is out of step with the cost and risk of providing homeowners coverage. California Insurance Commissioner Ricardo Lara has said these industry concessions are part of his "Sustainable Insurance Strategy" plan which is designed to keep as many private insurers operating in California as possible.&nbsp;
Another pressing issue with California's insurance market is that as more insurers exit the state, it only increases the number of homeowners relying on California's state-run FAIR Plan for insurance. Although FAIR advertises itself as an option of last resort, its website is getting thousands of applications per week from homeowners who are priced out by private rates.
Of course, all this only adds to the misery for any Travelers policyholder who just opened up their renewal envelope. They are likely to shop around and discover that they are the lucky ones to have gotten the option to renew at all. Many of their neighbors could be even worse off. The California insurance crisis has not yet affected homeowners as badly as the one in <a href="https://www.benzinga.com/real-estate/24/05/38851564/florida-lawmakers-propose-changing-tax-code-to-give-homeowners-insurance-premium-relief">Florida</a>, but it's trending in that direction.
Whatever happens, both the California Insurance Commission and the private insurers operating in the state will have to come to some sort of mutually beneficial arrangement. If they cannot, one of the world's most lucrative real estate markets could be in for an incredibly bumpy ride because it's simply impossible for a multi-trillion-dollar real estate market to exist if property owners can't get insurance.&nbsp;
Read Next:
<ul>
<li>Passive income investments are one of the most trusted methods for riding out a recession, so it's no surprise that people are turning to this <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">Jeff Bezos-backed startup to generate monthly rental income without having to purchase their own property</a>.</li>
<li>Commercial real estate has historically outperformed the stock market, but few investors have the capital or resources needed to invest in this asset class. This platform <a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate">allows individuals to invest in commercial real estate with as little as $5,000. </a></li>
</ul>